M&A Deal Summary |
|
---|---|
Date | 2017-01-26 |
Target | Actelion |
Sector | Life Science |
Buyer(s) | Johnson & Johnson |
Deal Type | Add-on Acquisition |
Deal Value | 30.0B USD |
Advisor(s) | BofA Securities Credit Suisse Investment Banking (Financial) Niederer Kraft & Frey Wachtell, Lipton, Rosen & Katz Slaughter and May (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1886 |
Sector | Consumer Products |
Employees | 132,000 |
Revenue | 85.2B USD (2023) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
DEAL STATS | # |
---|---|
Overall | 33 of 45 |
Sector (Life Science) | 12 of 18 |
Type (Add-on Acquisition) | 25 of 36 |
Country (Switzerland) | 3 of 3 |
Year (2017) | 1 of 3 |
Size (of disclosed) | 1 of 29 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-09-16 |
Abbott Medical Optics
Santa Ana, California, United States Abbott Medical Optics, Inc. is a manufacturer of ophthalmic surgery products and is known for world-class intraocular lenses used in cataract surgery. The World Health Organization estimates that approximately 20 million people are blind from age-related cataracts and that there are at least 100 million eyes with compromised visual acuity caused by cataracts. These numbers are steadily rising due to population growth and increasing life expectancy. |
Buy | $4.3B |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2017-02-15 |
Johnson & Johnson - Codman Neurosurgery Business
Raynham, Massachusetts, United States Johnson & Johnson - Codman Neurosurgery Business is a global neurosurgery and neurovascular company that offers a broad portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery, as well as aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke. |
Sell | $1.0B |